top of page

MitoSense Secures Japanese Patent for Groundbreaking Mitochondria-Based Therapy for Neurodegenerative Diseases

February 4, 2025 – Plymouth, MA – MitoSense Inc., a pioneering biotechnology company

specializing in mitochondria-based therapeutics, is proud to announce that it has been granted a

Japanese patent (Patent No. 7617652) for its innovative approach to treating neurodegenerative

diseases, including Amyotrophic Lateral Sclerosis (ALS). This milestone underscores

MitoSense’s commitment to revolutionizing medical treatments for neurodegenerative disorders

through its proprietary Mitochondria Organelle Transplantation (MOT™) technology.


The newly granted Japanese patent, titled "Compositions and Methods for the Treatment of ALS

and Other Neurodegenerative Diseases," covers the company’s cutting-edge methodology of

isolating and transplanting healthy mitochondria from donor cells into patients suffering from

mitochondrial dysfunction. This breakthrough therapy aims to restore cellular energy production

and mitigate disease progression, offering a novel and potentially transformative treatment for

patients worldwide.


"Securing this patent in Japan represents a significant step forward for MitoSense as we continue

to expand the global reach of our proprietary MOT technology," said Van Hipp, Chairman of

MitoSense. "With neurodegenerative diseases affecting over 55 million people worldwide,

including approximately 200,000 individuals suffering from ALS globally, our innovative

approach has the potential to change lives by addressing mitochondrial dysfunction at its core."


The Japanese patent builds upon MitoSense’s growing intellectual property portfolio,

complementing its recently secured U.S. patent for the same technology. As a leader in

mitochondrial research and therapeutics, MitoSense continues to advance clinical development

and strategic partnerships to bring this groundbreaking treatment to patients in need.


With this patent protection, MitoSense is poised to explore collaborations with leading Japanese

research institutions and pharmaceutical companies to accelerate the clinical application of its

mitochondrial transplantation technology in the region. This milestone strengthens MitoSense’s

position as an innovator in regenerative medicine and underscores the company’s commitment to

developing novel therapies for neurodegenerative diseases.


For more information on MitoSense Inc. and its groundbreaking research, please visit

www.mitosense.com.


About MitoSense Inc. MitoSense Inc. is a biotechnology company at the forefront of

mitochondrial research, developing revolutionary treatments for neurodegenerative and

metabolic disorders. The company’s Mitochondria Organelle Transplantation™ (MOT™)

technology aims to restore cellular function by introducing healthy mitochondria into

compromised cells, offering a promising new avenue for treating diseases linked to

mitochondrial dysfunction.

bottom of page